Dr. Koeffler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8700 Beverly Blvd.
Los Angeles, CA 90048Phone+1 310-423-4609Fax+1 310-423-7182
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 1976 - 1978- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1975 - 1976
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1972 - 1975
Baylor College of MedicineClass of 1972
Certifications & Licensure
CA State Medical License 1974 - 2024
American Board of Internal Medicine Internal Medicine
Clinical Trials
- Paricalcitol in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 2003 May 01
Publications & Presentations
PubMed
- 4 citationsMitophagy is a novel protective mechanism for drug-tolerant persister (DTP) cancer cells.Yun Li, Hengxing Chen, Daning Lu, H Phillip Koeffler, Yin Zhang
Autophagy. 2023-09-01 - 8 citationsTargeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy.Xue-Bin Ran, Ling-Wen Ding, Qiao-Yang Sun, Henry Yang, Jonathan W Said
Cancer Research. 2023-03-15 - 34 citationsPINK1-Mediated Mitophagy Promotes Oxidative Phosphorylation and Redox Homeostasis to Induce Drug-Tolerant Persister Cancer Cells.Yun Li, Hengxing Chen, Xuan Xie, Bing Yang, Xiaojuan Wang
Cancer Research. 2023-02-03
Journal Articles
- ARID1A and CEBPα Cooperatively Inhibit UCA1 Transcription in Breast CancerHarold Koeffler, MD, Nature
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
